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SGLT-2 inhibitors are a new class of oral diabetes medication that have been 
associated with a rare complication- euglycemic DKA. This case illustrates 
the importance of recognizing this clinical entity that can lead to a gapped 
metabolic acidosis in the setting of a normal glucose level.
CHIEF COMPLAINT: Vomiting, weakness, palpitations
HPI: A 34 year old female with a past medical history significant for AML s/p 
multiple past chemo treatments, DM Type 2, HTN, anxiety and depression 
presented to the ED  with head to toe generalized body aches x 4 days. 
Although her complaints ranged from chest pain to abdominal pain, she 
specifically came to the ED for evaluation of her fatigue after a night of 
vomiting >8 (non bloody) episodes and decreased po intake. 
PAST MEDICAL & SURGICAL HISTORY: Dx w AML in 2011, anxiety, 
depression, DM II, Hysterectomy
SOCIAL HISTORY: No smoking, alcohol or illicit drug use, no history of 




VITAL SIGNS: BP - 145/85    HR - 165     RR - 18    T - 99 F    O2 - 99% RA
GEN: Anxious, moaning in room
HEENT: PERRLA, EOMI, moderate DMM 
PULM: CTABL.
CARDS: Sinus tachy, no M/R/G. Good distal pulses.
ABD: Soft, nondistended, nontender. +BS.
SKIN: Warm, dry, no rashes.
NEURO: AAO x 3, CN II-XII intact.
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EUGLYCEMIC DKa: Although DKA is classically taught to include acidosis, hyperglycemia 
and increased plasma ketones, euglycemic DKA is basically DKA without the hyperglycemia. 
It is a more rare diagnosis; however, ED providers should have it on their differential of 
AGMA, specifically in diabetic patients on SGLT-2 inhibitors. 
MECHANISM: 
SGLT-2 inhibitors block sodium glucose co transporters in the proximal renal tubules which 
promotes glucose excretion. Just as in normal diabetic ketotic states, when the body cannot 
use blood glucose for energy, ketones and acidosis will ensue; however, since the overall 
glucose levels in the body are lower, the pt will be euglycemic.
TREATMENT: The treatment of euDKA is practically identical to the management of DKA 
with a few added caveats. 
• IV fluids with dextrose
• IV Insulin drip
• Frequent Glucose monitoring
























Having an anion gap metabolic acidosis of 16 with a 
bicarbonate of 8, the etiology was not readily 
apparent with the patient’s normal lactate, absence 

















Her expanded labs ultimately revealed a worsening acidosis with positive blood and urine 
ketones, leading to the diagnosis of euglycemic DKA.  She was admitted to the ICU on both 
an insulin and bicarbonate drip with dextrose containing fluids and frequent glucose checks. 
After her gap closed, her home medications revealed the culprit of this unique cause of DKA, 
her SGLT2 inhibitor which was immediately discontinued. 
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